Hypertriglyceridemia
Conditions
Keywords
Apolipoprotein A-V, LDL particle size, probiotic, triglyceride
Brief summary
The purpose of this study is to evaluate the effect of dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on triglyceride and apolipoprotein A-V.
Detailed description
A randomized, double-blind, placebo-controlled study was conducted on 128 nondiabetic and hypertriglyceridemic (Plasma Triglyceride, 150-500 mg/dL) subjects. Over a 12 week test period, the probiotic group consumed 2g of powder daily containing dual probiotic strains, while the placebo group consumed the same without probiotics.
Interventions
DIETARY_SUPPLEMENTplacebo
2g of powder daily without probiotics
DIETARY_SUPPLEMENTdual probiotics
2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
24 Years to 68 Years
Healthy volunteers
No
Inclusion criteria
* nondiabetic (plasma fasting glucose, \<126mg/dL; 2-hour plasma glucose, \<200mg/dL) * borderline to moderate hypertriglyceridemia (plasma triglyceride, 150-500 mg/dL)
Exclusion criteria
* lipid-lowering medications use * any medications or supplement use * any probiotics products use for the past 1 months * dyslipidemia * diabetes mellitus * hypertension * liver disease * renal disease * cardiovascular disease * cerebrovascular disease * pancreatitis * cancer * medication or alcohol abuse * pregnant or breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ApoA5-1131 genotype | at baseline | ApoA5-1131 T\>C |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting glucose at baseline and 12-week follow-up | 12-week follow-up | Serum fasting glucose (mg/dL) |
| Insulin at baseline and 12-week follow-up | 12-week follow-up | Serum insulin (μIU/dL) |
| C-peptide at baseline and 12-week follow-up | 12-week follow-up | Serum C-peptide (μEq/L) |
| Triglyceride at baseline and 12-week follow-up | 12-week follow-up | Serum triglyceride (mg/dL) |
| Free fatty acid at baseline and 12-week follow-up | 12-week follow-up | Serum free fatty acid (μEq/L) |
| Apolipoprotein A-V at baseline and 12-week follow-up | 12-week follow-up | Plasma apolipoprotein A-V (ng/mL) |
Other
| Measure | Time frame | Description |
|---|---|---|
| LDL particle size at baseline and 12-week follow-up | 12-week follow-up | Plasma LDL particle size (nm) |
| Serum high-sensitivity C-reactive protein at baseline and 12-week follow-up | 12-week follow-up | Serum high-sensitivity C-reactive protein (mg/dL) |
Countries
South Korea
Outcome results
None listed